This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	<i>Basic helix-loop-helix family, member e41 (BHLHE41; SHARP-1); cyclin G2 (CCNG2)</i>	<i>In vitro</i> studies and clinical specimen analysis suggest that expression of <i>SHARP-1</i> and <i>CCNG2</i> could be prognostic biomarkers of breast cancer. In gene expression datasets from primary breast cancer patients, those with low expression of <i>SHARP-1</i> and <i>CCNG2</i> had a significantly higher probability of cancer recurrence than patients with high expression of the gene signature. Next steps include investigating the mechanisms by which <i>SHARP-1</i> and <i>CCNG2</i> act as metastasis suppressors <i>in vivo</i> .	Patent application filed for prognosis of breast cancer patients by monitoring expression of <i>SHARP-1</i> and <i>CCNG2</i> ; unlicensed	Adorno, M. <i>et al. Cell</i> ; published online April 2, 2009; doi:10.1016/j.cell.2009.01.039 Contact: Stefano Piccolo, University of Padua, Padua, Italy e-mail: piccolo@civ.bio.unipd.it
		SciBX 2(14); doi:10.1038/scibx.2009.570 Published online April 9, 2009		